All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: A multinational, phase 3, multicohort study

The Lancet

Volumn 384, Issue 9954, 2014, Pages 1597-1605

  Manns, Michael ^a,b   Pol, Stanislas ^c   Jacobson, Ira M ^d   Marcellin, Patrick ^e   Gordon, Stuart C ^f   Peng, Cheng Yuan ^g   Chang, Ting Tsung ^h   Everson, Gregory T ⁱ   Heo, Jeong ^j   Gerken, Guido ^k   Yoffe, Boris ^l   Towner, William J ^m   Bourliere, Marc ⁿ   Metivier, Sophie ^o   Chu, Chi Jen ^p   Sievert, William ^q   Bronowicki, Jean Pierre ^r   Thabut, Dominique ^s   Lee, Youn Jae ^t   Kao, Jia Horng ^u   McPhee, Fiona ^v   Kopit, Justin ^v   Mendez, Patricia ^w   Linaberry, Misti ^w   Hughes, Eric ^w   Noviello, Stephanie ^w   more..

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^c Hôpital Cochin ^*  (France)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e BEAUJON HOSPITAL   (France)

^f HENRY FORD HEALTH SYSTEM   (United States)

^g CHINA MEDICAL UNIVERSITY   (Taiwan)

^h NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

ⁱ UNIVERSITY OF COLORADO   (United States)

^j Pusan National University Hospital   (South Korea)

^k UNIVERSITY OF DUISBURG ESSEN   (Germany)

^l BAYLOR COLLEGE OF MEDICINE   (United States)

^m KAISER PERMANENTE   (United States)

ⁿ HÔPITAL SAINT JOSEPH   (France)

^o CHU PURPAN   (France)

^p NATIONAL YANG MING UNIVERSITY   (Taiwan)

^q SOUTHERN HEALTH   (Australia)

^r UNIVERSITY HOSPITAL OF NANCY   (France)

^s PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^t Inje University College of Medicine   (South Korea)

^u NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^v BRISTOL MYERS SQUIBB   (United States)

^w BRISTOL MYERS SQUIBB RESEARCH AND DEVELOPMENT   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ASUNAPREVIR; DACLATASVIR; HEMOGLOBIN; LIVER ENZYME; PEGINTERFERON ALPHA; PLACEBO; RIBAVIRIN; VIRUS RNA; ANTIVIRUS AGENT; BMS-790052; IMIDAZOLE DERIVATIVE; ISOQUINOLINE DERIVATIVE; SULFONAMIDE;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; CHRONIC HEPATITIS; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EUROPE; FATIGUE; FEMALE; HEADACHE; HEART ATRIUM FIBRILLATION; HEMATOLOGIC DISEASE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1B; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NORTH AMERICA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SOUTH AMERICA; SUSTAINED VIROLOGICAL RESPONSE; THROMBOCYTE COUNT; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD; BLOOD; CLASSIFICATION; CLINICAL TRIAL; DRUG COMBINATION; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; ISOLATION AND PURIFICATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; VERY ELDERLY; VIROLOGY; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; ISOQUINOLINES; MALE; MIDDLE AGED; RNA, VIRAL; SULFONAMIDES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84906814530     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)61059-X     Document Type: Article

References (32)

1. World Health Organization. Hepatitis C key facts. WHO factsheet No 164. April, 2014. http://www.who.int/mediacentre/factsheets/fs164/en/ (accessed June 9, 2014).
2. Manos MM, Shvachko VA, Murphy RC, Arduino JM, Shire NJ. Distribution of hepatitis C virus genotypes in a diverse US integrated health care population. J Med Virol 2012;84:1744-50.
3. Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-74.
4. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2014;60:392-420.
5. Negro F, Alberti A. The global health burden of hepatitis C virus infection. Liver Int 2011;31(suppl 2):1-3.
6. Cornberg M, Razavi HA, Alberti A, et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int 2011;31(suppl 2):30-60.
7. Sievert W, Altraif I, Razavi HA, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int 2011;31(suppl 2):61-80.
8. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-87.
9. Jacobson IM, Dore GJ, Foster GR, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014; published online June 4. http://dx.doi.org/10.1016/S0140-6736 (14) 60494-3.
10. Manns M, Marcellin P, Fred Poordad FP, et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2014; published online June 4. http://dx.doi.org/10.1016/S0140-6736 (14) 60538-9.
11. Janssen Therapeutics. OLYSIO (Simeprevir) Prescribing information. 2014. http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/205123s001lbl.pdf (accessed June 9, 2014).
12. Manns MP, von Hahn T. Novel therapies for hepatitis C-one pill fits all? Nat Rev Drug Discov 2013;12:595-610.
13. Melia MT, Muir AJ, McCone J, et al. Racial differences in hepatitis C treatment eligibility. Hepatology 2011;54:70-78.
14. Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology 2014;146:1176-92.
15. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370:1594-603.
16. Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370:1604-14.
17. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483-93.
18. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:1889-98.
19. Gao M. Antiviral activity and resistance of HCV NS5A replication complex inhibitors. Curr Opin Virol 2013;3:514-20.
20. McPhee F, Sheaffer AK, Friborg J, et al. Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032). Antimicrob Agents Chemother 2012;56:5387-96.
21. Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012;366:216-24.
22. Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 2014;59:2083-91.
23. Bourliere M, Khaloun A, Wartelle-Bladou C, et al. Future treatment of patients with HCV cirrhosis. Liver Int 2012;32(suppl 1):113-19.
24. Suzuki Y, Ikeda K, Suzuki F, et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol 2013;58:655-62.
25. Chayama K, Takahashi S, Toyota J, et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 2012;55:742-48.
26. Everson GT, Sims KD, Rodriguez-Torres M, et al. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology 2014;146:420-29.
27. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014;370:211-21.
28. Food and Drug Administration. SOVALDI (sofosbuvir) prescribing information. 2014. http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/204671s000lbl.pdf (accessed June 9, 2014).
29. Zeuzem S, Hezode C, Bronowicki J-P, et al. Daclatasvir in combination with simeprevir ± ribavirin for hepatitis C virus genotype 1 infection. Top Antivir Med 2014;22(e-1):34-5.
30. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-28.
31. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-17.
32. Omata M, Kanda T, Yu ML, et al. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int 2012;6:409-35.